The global anti-obesity drugs market is projected to grow significantly from US$ 26.3 billion in 2024 to an estimated US$ 412.9 billion by 2034. This reflects a strong compound annual growth rate (CAGR) of 31.7% during the forecast period. North America currently leads the market, accounting for more than 46.4% of the total revenue, with US$ 12.2 billion in 2024. One major factor fueling market...